Boceprevir

Drugs of Today

Volumn 47, Issue 10, 2011, Pages 743-751

  Rizza, S A ^a   Talwani, R ^b   Nehra, V ^a   Temesgen, Zelalem ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; CLARITHROMYCIN; DIFLUNISAL; DROSPIRENONE; EFAVIRENZ; ETHINYLESTRADIOL; IBUPROFEN; KETOCONAZOLE; MIDAZOLAM; PEGINTERFERON; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; RITONAVIR; TENOFOVIR;

ANEMIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG CONCENTRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; END STAGE LIVER DISEASE; FATIGUE; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NAUSEA; PRACTICE GUIDELINE; RISK FACTOR;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HEPATITIS C; HUMANS; PROLINE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 81255211424     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.10.1656503     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention. Disease burden from viral hepatitis A, B, and C in the United States. http://www.cdc.gov/hepatitis/PDFs/ disease-burden.pdf. Accessed August 26, 2011.
2. World Health Organization. Hepatitis C Fact Sheet No 164, June 2011. http://www.who.int/mediacentre/factsheets/fs164/en/index.html. Accessed July 8, 2011.
3. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55(2): 245-64.
4. McHutchison, J.G., Lawitz, E.J., Shiffman, M.L. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361(6): 580-93.
5. Davis, G.L., Albright, J.E., Cook, S.F., Rosenberg, D.M. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9(4): 331-8. (Pubitemid 36443043)
6. Davis, G.L., Alter, M.J., El-Serag, H., Poynard, T., Jennings, L.W. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138(2): 513-21, 21 e1-6.
7. Lindenbach, B.D., Meuleman, P., Ploss, A. et al. Cell culture- grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 2006, 103(10): 3805-9. (Pubitemid 43376636)
8. Flores, M.V., Strawbridge, J., Ciaramella, G., Corbau, R. HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism. Biochim Biophys Acta 2009, 1794(10): 1441-8.
9. Venkatraman, S., Bogen, S.L., Arasappan, A. et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1- dimethylethyl)amino]carbonyl]amino]-3,3- dimethyl-1-oxobuty l]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan- 2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006, 49(20): 6074-86. (Pubitemid 44484951)
10. Raney, K.D., Sharma, S.D., Moustafa, I.M., Cameron, C.E. Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J Biol Chem 2010, 285(30): 22725-31.
11. Foy, E., Li, K., Wang, C., Sumpter, R., Jr., Ikeda, M., Lemon, S.M., Gale, M., Jr. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300(5622): 1145-8. (Pubitemid 36583099)
12. Malcolm, B.A., Liu, R., Lahser, F. et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006, 50(3): 1013-20. (Pubitemid 43327807)
13. Bartenschlager, R. Hepatitis C virus replicons: potential role for drug development. Nat Rev Drug Discov 2002, 1(11): 911-6. (Pubitemid 37361585)
14. Merck & Co. FDA Antiviral Drugs Advisory Committee Meeting, Boceprevir Capsules (NDA 202-258) Briefing Document, March 29, 2011. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials /Drugs/AntiviralDrugsAdvisoryCommittee/UCM252343. pdf. Accessed August 26, 2011.
15. Zhang, J., Gupta, S., Rouzier, R., et al. Single dose pharmacokinetics of a novel hepatitis C protease inhibitor, SCH 503034, in an oral capsule formulation. Hepatology [56th Annu Meet Am Assoc Study Liver Dis (Nov 11-15, San Francisco) 2005] 2005, 42(4, Suppl. 1): 535A.
16. Ghosal, A., Yuan, Y., Tong, W. et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011, 39(3): 510-21.
17. Victrelis [package insert]. 2011 Schering Corporation, a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ 08889, USA.
18. Kwo, P.Y., Lawitz, E.J., McCone, J. et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376(9742):705-16.
19. Poordad, F., McCone, J., Jr., Bacon, B.R. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364(13): 1195-206.
20. Bacon, B.R., Gordon, S.C., Lawitz, E. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364(13): 1207-17.
21. Schiff, E., Poordad, F., Jacobson, I. et al. Boceprevir (B) combination therapy in null responders (NR): Response dependent on interferon responsiveness. 43rd Annu Meet Eur Assoc Study Liver (EASL) (April 23-27, Milan) 2008, Abst 104.
22. McHutchison, J.G., Manns, M., Patel, K. et al. Adherence to combination therapy enhances sustained response in genotype- 1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123(4): 1061-9.
23. Marcellin, P., Chousterman, M., Fontanges, T. et al. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int 2011, 31(4): 516-24.